Juglanin

CAS No. 5041-67-8

Juglanin( —— )

Catalog No. M24463 CAS No. 5041-67-8

Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 260 In Stock
10MG 386 In Stock
25MG 626 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Juglanin
  • Note
    Research use only, not for human use.
  • Brief Description
    Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.
  • Description
    Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.
  • In Vitro
    Cell Viability Assay Cell Line:MCR-5 cell Concentration:0-40 μM Incubation Time:0-72 h Result:Reduced the cell viability of MCR-5 after 24 h exposure at 160 μM.Reduced the cell viability of MCR-5 after 72 h exposure at 40 μM.Western Blot Analysis Cell Line:MCF-7, SKBR3 Concentration:0-10 μM Incubation Time:24 hResult:Increased the expressions of phosphorylated Chk2, Chk2, phosphorylated Cdc25C, phosphorylated Cdc2, p27, cyclin D, Bad, Bax and decreased the levels of Cdc25C, Cdc2, Bcl-2.Activated caspases and led to Casapse-9, Casapse-8 and Caspase-3 cleavage.Increased the level of JNK phosphorylation.Western Blot Analysis Cell Line:Lipopolysaccharides (LPS, HY-D1056)-treated AST cells Concentration:40-160 μM Incubation Time:24 h Result:Decreased the expression of TLR4, MyD88, CD14, p-IKKα, p-IκBα, p-NF-κB, GFAP, BDNF, Aβ and p-Tau induced by LPS (HY-D1056).Increased the level of SYP, PSD-25 and SNAP-25.
  • In Vivo
    Animal Model:Tumor-transplanted mouse model Dosage:10-20 mg/kg Administration:Intraperitoneal injection (i.p.), daily, 7 daysResult:Increased levels of cleaved Caspase-9 and Caspase-3, LC3BI, LC3BII and phosphorylated JNK.Increased dead cells and apoptosis proportion in juglanin-treated tumor tissues.Increase in mean areas that stained positively cleaved Caspase-3 in juglanin-treated tumor tissues.Animal Model:C57BL6 male miceDosage:10-30 mg/kg Administration:Intraperitoneal injection (i.p.), 5 times weekly Result:Increased number of platform crossings and expanded time in target quadrant.Decreased the expression level of α-synuclein, pro-inflammatory cytokines (IL-1β, TNF-α, IL-18 and COX-2), TLR-4, MyD88, CD14, Aβ, phosphorylation of Tau, Ibal and neurotrophic factor (BDNF).Reversed LPS-triggered effect on synaptic markers, up-regulating the expression of SYP, PSD-95 and SNAP-25.Restored TH levels in the hippocampus of mice in a dose-dependent manner.Decreased p-IKKα, p-IκBα and p-NF-κB levels combinated with LPS.Decreased the GFAP-positive cells.Animal Model:C57BL/6 male mice Dosage: 80 mg/kg Administration:i.g., daily, 1-21 days Result:Improved the survial rate of the BLM (HY-108345)-treated mice.Decreased the expression of BALF, CXCL1, IL-6, TNF-α, MPO activity, TGF-β1, and its down-streaming proteins (fibronectin/MMP-9/α-SMA/collagen I).Reduced the number of total cells, neutrophils and macrophages in BALF.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis|Autophagy|JNK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    5041-67-8
  • Formula Weight
    418.35
  • Molecular Formula
    C20H16O10
  • Purity
    >98% (HPLC)
  • Solubility
    Methanol:16 mg/mL (38.25 mM; Need ultrasonic)
  • SMILES
    O=C1C(O[C@H]2[C@@H]([C@H]([C@H](CO)O2)O)O)=C(C3=CC=C(O)C=C3)OC4=CC(O)=CC(O)=C14
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Sun ZL, et al. Juglanin induces apoptosis and autophagy in human breast cancer progression via ROS/JNK promotion. Biomed Pharmacother. 2017 Jan;85:303-312.
molnova catalog
related products
  • Pivanex

    Pivanex is an orally active HDAC inhibitor and an antimetastatic and antiangiogenic agent. Pivanex downregulates the Bcr-Abl protein and enhances apoptosis.

  • CP 461

    CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2.

  • AFMK

    AFMK is an active metabolite of Melatonin with antioxidant and free radical scavenging activity. AFMK is a modulator of apoptosis and improves the anti-tumor effect of Gemcitabine in PANC-1 cells.